Get started
Author

Erik de Cabo

Observed names: E. De Cabo, Erik De Cabo, Erik De Cabo López, Erik De Cabo López, Erik De Cabo-Lopez, Erik de Cabo López
Institution: Hospital El Bierzo
ORCID: 0000-0001-8697-5594
Observed ORCID: 0000-0001-8697-5594
OpenAlex ID: A5042140394
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
2014 · Tomás José González‐López, Cristina Pascual, et al. · American Journal of Hematology · 149
PDF
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
2017 · Sara Alonso‐Álvarez, Laura Magnano, et al. · British Journal of Haematology · 79
PDF
Safety and efficacy of splenectomy in over 65‐yrs‐old patients with immune thrombocytopenia
2013 · Jose R. Gonzalez‐Porras, Fernando Escalante, et al. · European Journal Of Haematology · 62
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
2017 · Tomás José González-López, Fernando Fernández-Fuertes, et al. · International Journal of Hematology · 54
Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice
2024 · Tomás José González-López, Nuria Bermejo-Vega, et al. · Blood · 52
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
2015 · Tomás José González‐López, María Teresa Alvarez‐Román, et al. · European Journal Of Haematology · 48
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
2021 · Tomás Palanques-Pastor, Juan Eduardo Megías-Vericat, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 34
PDF
Life Expectancy of Follicular Lymphoma Patients in Complete Response at 30 Months is Similar to that of the Spanish General Population
2018 · Laura Magnano, Sara Alonso‐Alvarez, et al. · British Journal of Haematology · 33
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
2021 · Tamara Castaño-Bonilla, Juan M. Alonso-Dominguez, et al. · Scientific Reports · 28
PDF
Successful Discontinuation of Eltrombopag after Complete Remission in Patients with Primary Immune Thrombocytopenia
2014 · Tomás José González-López, Cristina Pascual, et al. · Blood · 27
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia
2014 · Tomás José González-López, Blanca Sánchez-González, et al. · Platelets · 21
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study
2025 · Lucía Pérez-Lamas, Adrián Segura Diaz, et al. · Blood Cancer Journal · 13
PDF
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
2021 · Paula Rodriguez-Otero, Maialen Sirvent, et al. · Clinical Lymphoma Myeloma & Leukemia · 12
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia
2019 · Tomás José González‐López, Blanca Sánchez‐González, et al. · European Journal Of Haematology · 12
PDF
Cutaneous Findings in a Case of Mediterranean Spotless Fever Due to Rickettsia conorii, With Gangrene of Multiple Toes
2013 · Angel Fernandez-Flores, Erik De Cabo-Lopez, et al. · American Journal of Dermatopathology · 7
Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry
2020 · Pilar Martínez, Tomás Palanques Pastor, et al. · Blood · 4
PDF
Sustained Response After Short-Medium-Term Treatment With Eltrombopag In Patients With ITP
2013 · Tomás José González-López, José Ramón González-Porras, et al. · Blood · 4
Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
2024 · Lucía Pérez-Lamas, Adrian Segura Diaz, et al. · Blood · 3
PDF
P1639: Utility of Next Generation Sequencing Techniques to Evaluate Possible Causes of Refractoriness to Treatment With Eltrombopag in Adult Patients With Primary Immune Thrombocytopenia (itp) in Spain.
2022 · T. J. Gonzalez-Lopez, R. Sanchez, et al. · HemaSphere · 2
Incidence, Risk Factors and Prognosis of Transformation in Follicular Lymphoma: a Multicentre Retrospective Analysis of 1763 Patients from the Geltamo Spanish Lymphoma Cooperative Group
2015 · Sara Alonso*, Miguel Alcoceba*, et al. · Blood · 2
Early Identification of Very High Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) By PET-CT
2023 · Almudena Cabero Martínez, Luis Gonzaga Diaz Gonzalez, et al. · Blood · 1
Efficacy and Safety of Eltrombopag in Persistent and Newly Diagnosed ITP
2015 · Tomás José González-López, Blanca Sánchez-González, et al. · Blood · 1
The mutational landscape of resistance to BTK and BCL2 inhibitors in CLL: a real-world multicentric study
2026 · Miguel Bastos-Boente, María García-Álvarez, et al. · Blood Cancer Journal
PDF
Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival
2026 · Borja Puertas, Irene Padilla, et al. · British Journal of Haematology
PDF
Molecular predictors of anemia response to momelotinib in patients with myelofibrosis: Real-world outcomes from the momgemfin study.
2025 · Adrian Segura Diaz, Lucia Perez Lamas, et al. · Blood
Works count: 28
Citation count: 648
H-index: 12
I10-index: 14
Year
Topic
Type